USA-based BioXcel Therapeutics (Nasdaq: BTAI), a biopharma using artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, has announced strategic financing agreements with funds managed by Oaktree Capital Management and Qatar Investment Authority (QIA).
Under the agreements, Oaktree and QIA will provide up to $260 million in gross funding to support the company’s commercial activities of Igalmi (dexmedetomidine) sublingual film, a product indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.
"We have never been in a better position to realize our vision of becoming the leading AI-enabled neuroscience company"This financing is also intended to support the expansion of development efforts of BXCL501, which includes a pivotal Phase III program for the acute treatment of agitation in patients with Alzheimer’s disease (AD), and for its additional neuroscience and immuno-oncology clinical programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze